# HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies

> **NCT06649708** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hanx Biopharmaceuticals (Wuhan) Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Solid Tumor Malignancies

## Interventions

- **DRUG:** HX044

## Key facts

- **NCT ID:** NCT06649708
- **Lead sponsor:** Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2025-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06649708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06649708, "HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06649708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*